Cas No.: | 943540-74-7 |
Chemical Name: | 6-(difluoro(6-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)quinoline |
Synonyms: | OMO1;JNJ38877618;OMO-1 |
Formula: | C20H12F2N6 |
M.Wt: | 374.355 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively; potently inhibits MET receptor phosphorylation and downstream pathway modulation in the nanomolar range and induces anti-proliferative and anti-migratory activity in models with MET gene amplification, mutant or ligand-mediated pathway activation; completely suppresses tumour growth SNU5 MET amplified gastric, U87-MG HGF autocrine glioblastoma and Hs746T MET exon 14 skipping mutant gastric cancer models. Solid Tumors Phase 1 Clinical |